Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN

American Journal of Hematology

Volumn 87, Issue 5, 2012, Pages 552-554

  Antonioli, Elisabetta ^a   Guglielmelli, Paola ^b   Pieri, Lisa ^b   Finazzi, Mariachiara ^c   Rumi, Elisa ^d   Martinelli, Vincenzo ^e   Vianelli, Nicola ^f   Luigia Randi, Maria ^g   Bertozzi, Irene ^g   De Stefano, Valerio ^h   Za, Tommaso ^h   Rossi, Elena ^h   Ruggeri, Marco ⁱ   Elli, Elena ^j   Cacciola, Rossella ^k   Cacciola, Emma ^k   Pogliani, Enrico ^j   Rodeghiero, Francesco ⁱ   Baccarani, Michele ^f   Passamonti, Francesco ^l   Finazzi, Guido ^c   Rambaldi, Alessandro ^c   Bosi, Alberto ^b   Cazzola, Mario ^d   Barbui, Tiziano ^c   Vannucchi, Alessandro M ^b   more..

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

ⁱ SAN BORTOLO HOSPITAL   (Italy)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

^l AOU Fondazione Macchi   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; BUSULFAN; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; PIPOBROMAN;

ABSENCE OF SIDE EFFECTS; ACTINIC KERATOSIS; DERMATITIS; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSCHROMIC LESION; FEVER; HUMAN; LETTER; MUCOSAL DISEASE; MULTICENTER STUDY (TOPIC); MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PNEUMONIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SKIN DEFECT; SKIN ULCER; THROMBOCYTHEMIA; THROMBOCYTOPENIA; ULCER;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES; CARCINOMA, SQUAMOUS CELL; DRUG ERUPTIONS; FEMALE; FEVER; HUMANS; HYDROXYUREA; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYELOPROLIFERATIVE DISORDERS; PNEUMONIA; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SKIN ULCER; YOUNG ADULT;

EID: 84859922985     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23160     Document Type: Letter

References (14)

1. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-770.
2. Saban N, Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother Pharmacol 2009; 64: 213-221.
3. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-1136.
4. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
5. Martinez-Trillos A, Gaya A, Maffioli M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010; 89: 1233-1237.
6. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497-1503.
7. Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: Results of a consensus process by an international working group. Leukemia 2007; 21: 277-280.
8. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 2010; 148: 961-963.
9. Verstovsek S, Passamonti F, Rambaldi A, et al. A Phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea. Blood 2009; 114: 311A.
10. Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010; 150: 446-455.
11. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-1097.
12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
13. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999; 104: 730-737.
14. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 2008; 22: 437-438.